Viking Therapeutics, a biopharmaceutical firm, announced Tuesday that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a product candidate meant to treat high cholesterol and fatty liver disease.

An approved IND would allow the San Diego company to start a Phase 2 trial of the product, VK2809.

“Together with our recently initiated Phase 2 clinical trial of VK5211, our lead program for muscle and bone disorders, the Phase 2 VK2809 study will represent the second key clinical trial we will have underway by year end,” said Brian Lian, chief executive officer of Viking, in a statement.

Viking expects to initiate the Phase 2 clinical trial by the end of 2015.